Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S224000, C548S110000
Reexamination Certificate
active
07868033
ABSTRACT:
Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are benzoxazoles and related compounds.
REFERENCES:
patent: 3551443 (1970-12-01), Duennenberger et al.
patent: RE29608 (1978-04-01), Evans et al.
patent: 4107169 (1978-08-01), Schrage
patent: 4416892 (1983-11-01), Dawson
patent: 5037842 (1991-08-01), Goldstein
patent: 5200420 (1993-04-01), Goldmann et al.
patent: 5254692 (1993-10-01), Goldmann et al.
patent: 5354759 (1994-10-01), Oku et al.
patent: 5412099 (1995-05-01), Goldmann et al.
patent: 5441946 (1995-08-01), Pauls et al.
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5563128 (1996-10-01), Pauls et al.
patent: 5714496 (1998-02-01), Brown et al.
patent: 5837390 (1998-11-01), Kishii et al.
patent: 6107491 (2000-08-01), Eldin
patent: 6277853 (2001-08-01), Perez et al.
patent: 6420418 (2002-07-01), Hagmann et al.
patent: 6495568 (2002-12-01), Dack et al.
patent: 6544989 (2003-04-01), Mathews et al.
patent: 6589953 (2003-07-01), Perez et al.
patent: 6602619 (2003-08-01), Lin et al.
patent: 6623930 (2003-09-01), Kerwin et al.
patent: 6689887 (2004-02-01), Kerwin et al.
patent: 6693098 (2004-02-01), Cournoyer et al.
patent: 6794403 (2004-09-01), Malamas et al.
patent: 2001/0056100 (2001-12-01), Cournoyer et al.
patent: 2002/2049142 (2002-04-01), Mathews et al.
patent: 2002/2061891 (2002-05-01), Perez et al.
patent: 2002/2107258 (2002-08-01), Kerwin et al.
patent: 2003/0040525 (2003-02-01), Kerwin et al.
patent: 2003/0129448 (2003-07-01), Lin et al.
patent: 2003/0199562 (2003-10-01), Malamas et al.
patent: 2003/0220367 (2003-11-01), Cournoyer et al.
patent: 2003/0232877 (2003-12-01), Sikorski et al.
patent: 2004/0006056 (2004-01-01), Harris et al.
patent: 2004/0029933 (2004-02-01), Zhao et al.
patent: 2004/0048858 (2004-03-01), Sikorski et al.
patent: 2004/0102435 (2004-05-01), Barlaam et al.
patent: 2004/0152140 (2004-08-01), Kelly et al.
patent: 2004/0209776 (2004-10-01), Farooq et al.
patent: 2004/0229894 (2004-11-01), Kerwin et al.
patent: 274490 (1913-05-01), None
patent: 602336 (1934-08-01), None
patent: 2 314 238 (1974-09-01), None
patent: 4208535 (1992-09-01), None
patent: 4304650 (1994-08-01), None
patent: 0 479 161 (1992-04-01), None
patent: 0 611 660 (1994-08-01), None
patent: 04-183754 (1992-06-01), None
patent: 5-17458 (1993-01-01), None
patent: 06-073050 (1994-03-01), None
patent: 06-073051 (1994-03-01), None
patent: 06-239849 (1994-08-01), None
patent: 6336586 (1994-12-01), None
patent: 07-097379 (1995-04-01), None
patent: 09227576 (1997-09-01), None
patent: 09328678 (1997-12-01), None
patent: 09165391 (1999-06-01), None
patent: 2000100569 (2000-04-01), None
patent: 2001055332 (2001-02-01), None
patent: 2001064166 (2001-03-01), None
patent: 2001064205 (2001-03-01), None
patent: 2001242165 (2001-09-01), None
patent: 2001291593 (2001-10-01), None
patent: 2001301329 (2001-10-01), None
patent: 2002003368 (2002-01-01), None
patent: 2004250411 (2004-09-01), None
patent: 2004302049 (2004-10-01), None
patent: WO 98/27972 (1998-07-01), None
patent: WO 00/78733 (2000-12-01), None
patent: WO 01/12183 (2001-02-01), None
patent: WO 01/14354 (2001-03-01), None
patent: WO 01/27088 (2001-04-01), None
patent: WO 01/74786 (2001-10-01), None
patent: WO 02/16333 (2002-02-01), None
patent: WO 02/46168 (2002-06-01), None
patent: WO 02/051821 (2002-07-01), None
patent: WO 03/020698 (2003-03-01), None
patent: WO 03/045930 (2003-06-01), None
patent: WO 03/074516 (2003-09-01), None
patent: WO 03/089418 (2003-10-01), None
patent: WO 2004/046123 (2004-06-01), None
patent: WO 2004/056315 (2004-07-01), None
patent: WO 2004063155 (2004-07-01), None
patent: WO 2004/064771 (2004-08-01), None
patent: WO 2004/083189 (2004-09-01), None
patent: WO 2004/083195 (2004-09-01), None
patent: WO 2004/084824 (2004-10-01), None
patent: WO 2004/092140 (2004-10-01), None
patent: WO 2004/094395 (2004-11-01), None
patent: WO 2004/098494 (2004-11-01), None
Stephens et al. Journal of the Chemical Society 1950, 1722-6.
March, J. Advanced Organic Chemistry John Wiley & Sons, 4th Ed., 1992.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Sacchettini et al. Nature Reviews Drug Discovery Apr. 2002, 1, 267-275.
FoldRx Press Release, Jul. 21, 2009.
Announcement from Business Wire, Nov. 20, 2008.
www.wrongdiagnosis.com/t/transthyretin—amyloidosis/symptoms.htm, Jul. 21, 2009.
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
Hari et al., “Extending the Scope of Chromium-Manganese Redox-Coupled Reactions: A One-Pot Synthesis of Benzoxazoles,” J. Org. Chem. (2001), 66:992-996.
Miller, N., “The Misfolding Diseases Unfold”, Beremans, Ltd., (2004), pp. 1-4.
Steadman, T. “Stedman's Medial Dictionary” 27thed., Lippincott Williams & Wilkins, (2000), p. 65.
Aydin et al., “Analgesic and antispasmodic activities of 2-(2-nitro-phenyl)-1-H-benzimidazole 5-carobxylic acid: evidence for the importance of the 2-(o-substituted phenyl) group,” Pharmazie, vol. 58, No. 6, 2003, pp. 405-408.
Baures et al., “Synthesis and Evaluation of Inhibitors of Transthyretin Amyloid Formation Based on the Non-Steroidal Anit-inflammatory Drug, Flufenamic Acid,” Bioorganic & Medicinal Chemistry, vol. 7, 1999, pp. 1339-1347.
Baures et al., “Discovering Transthyretin Amyloid Fribril Inhibitors by Limited Screening,” Bioorganic & Medicinal Chemistry, vol. 6, 1998, pp. 1389-1401.
Beaulieu et al., “Non-nucleoside Inhibitors of the Hepatitis C virus NS5B Polymerase: Discovery and Preliminary SAR of Benzimidazole Derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 14, 2004, 119-124.
Essassi et al., “Synthese Et Hererocyclisation Des (Pyrazolyl-3(5))-2 Benzimidazoles En Catalyse Par Transfert De Phase,” Bulletin De La Société Chimique Belge, vol. 96, No. 1, 1987, pp. 63-68.
Göker et al., “Synthesis and Antimicrobial Activity of Some New 2-Phenyl-N-Substituted Carboxamido-1H-benzimidazole Derivatives,” Archiv Der Pharmazie, vol. 334, 2001, pp. 148-152.
Green et al., “Synthesis and Characterization of Potent Bivalent Amyloidosis Inhibitors That Bind Prior to Transthyretin Tetramerization,” J. Am. Chem. Soc., vol. 125, 2003, pp. 13404-13414.
Hammarström et al., “Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics,” Science, vol. 299, 2003, pp. 713-713.
Hammarström et al., “Trans-Suppression of Misfolding in an Amyloid Disease,” Science, vol. 293, 2001, 2459-2462.
Haskell et al., “Neuraminidase Inhibition and Viral Chemotherapy,” Journal of Medicinal chemistry, American Chemical Society, Washington, US, vol. 13, No. 4, Jul. 1970, pp. 697-704.
Hilliard et al., “Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems,” Antimicrobial Agents and Chemotheraphy, vol. 43, No. 7, Jul. 1999, pp. 1693-1699.
Hisano et al., “Synthesis of Organosulfur Compounds. VIII.1)Cyclization Products from the Modified Willgerodt-Kindler Reaction2),” Chem. Pharmaceutical Bulletin, vol. 21, 1973, pp. 511-517.
Jennings et al., “Efficient Synthesis of (±)-seco-Cyclopropaneindoline Analogs of CC-1065,” Heterocyclic Communications, vol. 7, No. 1, 2001, pp. 7-16.
Kelly et al., “The Environment Dependency of Protein Folding Best Explains Prion and Amyloid Diseases,” PNAS, vol. 95, PNAS, pp. 930-932, 1998.
Kim et al., “Structure-Activity Relationships of Benzimidazoles and Related Heterocycles as Topoisomerase I Poisons,” Bioorganic & Medicinal Chemistry, vol. 4, 1996, pp. 621-630.
Klabunde et al., “Rational Design of Potent Human Transthyretin Amyloid Disease Inhibitors,” Nature Structural Biology, vol. 7, No. 4, 2000, pp.
Anderson Rebecca L
Fish & Richardson P.C.
FoldRx Pharmaceuticals, Inc.
Nolan Jason M
LandOfFree
Compounds, compositions and methods for stabilizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions and methods for stabilizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions and methods for stabilizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683473